A5059854479- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Integrated Circuits and Semiconductor Failure Analysis
- Chemotherapy-induced cardiotoxicity and mitigation
- Polyomavirus and related diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Mast cells and histamine
- Biosimilars and Bioanalytical Methods
- T-cell and Retrovirus Studies
- Protein Degradation and Inhibitors
The University of Texas Southwestern Medical Center
2018-2025
The Ohio State University
2014-2024
University of Saskatchewan
2024
Southwestern Medical Center
2020-2024
Harold C. Simmons Comprehensive Cancer Center
2022-2024
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2006-2023
Augusta University
2009-2022
The Ohio State University Wexner Medical Center
2014-2022
Georgia Regents Medical Center
2013-2014
Augusta University Health
2011-2013
Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment chronic lymphocytic leukemia (CLL). However, also irreversibly inhibits alternative targets, which potentially compromises its index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that specifically designed to improve on safety and efficacy first-generation inhibitors.In this uncontrolled, phase 1-2, multicenter study, we administered...
<h3>Importance</h3> The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy this drug and outcomes following discontinuation have not been evaluated outside of clinical trials relatively short follow-up. <h3>Objective</h3> To determine features associated outcomes. <h3>Design, Setting, Participants</h3> A total 308 participating 4 sequential at Ohio State University Comprehensive Cancer Center...
Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and lack effective treatment options. The multikinase inhibitor midostaurin inhibits KIT D816V, primary driver of disease pathogenesis. We conducted an open-label study oral at dose 100 mg twice daily in 116 patients, whom 89 mastocytosis-related organ damage were eligible for inclusion the efficacy population; 16 had aggressive mastocytosis, 57 neoplasm, mast-cell leukemia. outcome...
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift therapy, and relapse been uncommon current follow-up. Acquired mutations BTK PLCG2 can cause relapse, but data regarding the prevalence natural history these are limited. Patients Methods accrued four sequential studies were included analyses. Deep sequencing for was performed retrospectively on patients who experienced prospectively screening population....
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell (ITK). The relative importance of these 2 kinases not examined despite its relevance immune-based therapies.
Key Points Acalabrutinib had good tolerability in patients with relapsed or refractory CLL who were intolerant to ibrutinib. demonstrated a high response rate (81%)
Chronic lymphocytic leukemia (CLL) and small lymphoma (SLL) are essentially different manifestations of the same disease that similarly managed. A number molecular cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual at end treatment chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor improved survival among patients previously untreated relapsed/refractory CLL/SLL. The selection based on stage, presence...
Purpose Lenalidomide is a novel therapeutic agent with uncertain mechanism of action that clinically active in myelodysplastic syndrome (MDS) and multiple myeloma (MM). Application high (MM) low doses lenalidomide has been reported to have clinical activity CLL. Herein, we highlight life-threatening tumor flare when higher are administered patients CLL provide potential for its occurrence. Patients Methods Four relapsed were treated (25 mg/d 21 days 28-day cycle). Serious adverse events...
Atrial fibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data regarding the management AF this patient population are limited, and stroke prevention poses a challenge because increased risk bleeding with ibrutinib treatment. Our study sought describe incidence adult treated for hematologic malignancy, assess strategies, evaluate outcomes, identify factors occurrence. Of 582 ibrutinib, 76 developed AF. With median follow-up 32 months, estimated cumulative at 6 1...
Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here, we describe preclinical investigations ARQ 531, a potent, reversible BTK additional activity against Src family kinases and related to ERK signaling. We hypothesized that targeting would improve global signaling pathways, producing more robust responses. In vitro treatment patient CLL...
Natural killer (NK)-cell count is predictive of chronic lymphoid leukemia (CLL) disease progression and their dysfunction well documented, but the etiology this currently lacking. CLL cells have been shown to over-express HLA-E, natural ligand for NKG2A expressed on NK-cells that generates a distinct negative signal relative direct NK-cell cytotoxicity in other models. Utilizing novel anti-NKG2A monoclonal blocking antibody (mAb), monalizumab, we explored vitro preclinical activity targeting...
The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy.This phase II study tested a combination regimen obinutuzumab, ibrutinib, and venetoclax total 14 cycles in both patients with treatment-naïve (n = 25) relapsed or refractory to determine response therapy safety.The primary end point was rate complete remission undetectable minimal residual disease by...
The treatment landscape of chronic lymphocytic leukemia/small lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 emerged as an effective chemotherapy-free option for patients previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end is emerging important predictor progression-free overall survival treated fixed-duration inhibitor-based treatment. These NCCN...
<h3>Importance</h3> Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy autologous hematopoietic cell transplant (AHCT) is an accepted effective strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. <h3>Objective</h3> To assess outcomes in patients with PCNSL undergoing AHCT 3 most commonly used regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU),...
Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT receipt CAR T are limited. We report a multicenter retrospective study assessing safety, toxicities, outcomes in LBCL following failure. Eighty-eight with relapsed, refractory received an anti-CD19 The median number lines between...